Clinical and Translational Challenges in Thyroid Cancer

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• Thyroid cancer is the most common endocrine malignancy, accounting for 1% of all new tumors.
• Differentiated thyroid carcinomas (DTC) and medullary thyroid carcinoma (MTC) have significant metastatic potential, and anaplastic thyroid carcinoma is highly aggressive.
• Current treatments for DTC and MTC are limited, with only four approved drugs, and significant unmet needs exist regarding resistance and side effects.

Purpose of the Study:

• To review the current molecular landscape and treatment strategies for thyroid cancers.
• To discuss ongoing research into new drugs and drug combinations targeting driver mutations (e.g., BRAF, RET).
• To explore the potential role of systemic therapies like immunotherapy and peptide receptor radionuclide therapy in advanced thyroid cancer management.

Main Methods:

• Literature review of current molecular understanding and treatment of thyroid cancers.
• Analysis of ongoing clinical and translational research.
• Discussion of novel therapeutic approaches and drug combinations.

Main Results:

• Limited approved therapies exist for differentiated and medullary thyroid carcinomas.
• Resistance to treatment and off-target side effects are significant challenges.
• Targeting driver mutations (BRAF, RET) and exploring systemic therapies are key research directions.

Conclusions:

• There is a critical need for novel therapeutic strategies for advanced thyroid cancers.
• Inhibiting driver mutations and utilizing systemic therapies like immunotherapy show promise for improving patient outcomes.
• Future management of advanced thyroid cancers will likely involve molecularly targeted agents and novel systemic treatments.